

COVID-19 Update

Dr Mark Cunningham-Hill
Medical Director NEBGH

Dr Lindsay E. Jubelt, MD
Chief Medical Officer, VP of Operations
Mount Sinai Solutions

Monday April 20th

NYS COVID-19 Data

■ Cases ■ Hospitalizations ■ Deaths

7000

6000

5000

4000

3000

2000

1000

0



<https://www1.nyc.gov/site/doh/covid/covid-19-data.page>

COVID-19 Return to Work

Lindsay E. Jubelt, MD
Mount Sinai Health System

April 20, 2020



**Mount
Sinai**

Return to Work: Framework

Key Considerations for a Phased Reopening Plan



1. Sustained **reduction in cases**



2. Determine which business services are **essential**



3. Understand the **risk of infection** associated with reopening



4. Ensure workplaces are **designed to keep employees safe**



5. Require **face coverings** when taking public or private transport



Key Pillars: *Strengthened Healthcare Systems, Testing, and Contact Tracing*

Return to Work: Testing

	1 Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR)	2 Rapid Diagnostic Test (RDT)	3 Enzyme-Linked Immunosorbent Assay (ELISA)
Test Type	Diagnoses COVID-19	Detects presence of antibodies	Detects presence <i>and amount</i> of antibodies
Sample Type	Nasal, Throat, or Saliva	Blood	Blood
Test Site	Lab or Point-of-Care	Point-of-Care	Lab
Sensitivity	95%	80% - 90%	85% - 90%
Specificity	95%	95%	90 – 95%
# FDA Authorized*	33	2	2

*Note: Tests that have been authorized by the FDA under Emergency Use Authorization (EUA) as of 4/17/2020

Return to Work: Immunity to COVID-19

How Does Immunity Work?

- In response to a COVID infection, the immune system creates IgG and IgM antibodies
- IgG and IgM bind to and inactivate infected cells
- IgM provides short-term protection
- IgG stays in blood, conferring long-term immunity
- Immunity duration can range from a year to lifetime

What We Know So Far


- Immunity for closely-related coronaviruses like SARS and MERS inform our thinking on COVID

1 – 2

Length of SARS Immunity (years)¹

2 – 3

Length of MERS Immunity (years)²



1. Mo et. al, "Longitudinal Profile of Antibodies Against SARS Coronavirus in SARS Patients and their Clinical Significance," Asian Pacific Society of Respiriology, January 2006

2. Payne et. al, "Persistence of Antibodies Against Middle East Respiratory Syndrome Coronavirus," Emerging Infectious Diseases, October 2016

Return to Work: Temperature Screening

- **EEOC allows employers to implement temperature screening programs**

On March 17, 2020, the U.S. Equal Employment Opportunity Commission (EEOC) issued an update to guidance that expressly grants employers the ability to implement temperature screening measures in response to the current COVID-19 pandemic.

- **Effectiveness of temperature screening programs are variable**

Effectiveness depends on a number of factors:

Factor	COVID-19 Data
Illness incubation period	Median is ~5 days
Proportion of subclinical cases	5-50%
Sensitivity of thermal scanners to detect fever	Variability by device and operator

#HereComesTheSun

The joyful “Here Comes the Sun” blasts overhead on the public address system at Mount Sinai South Nassau in Oceanside every time a COVID-19 patient is discharged



We will get through this!